menu
    • menu
    [{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"CSF1R kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"CSF1R","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Vimseltinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Vimseltinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Vimseltinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Vimseltinib

    Menu

    Vimseltinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Accepts Deciphera’s NDA for Vimseltinib to Treat Tenosynovial Giant Cell Tumor

                            Details : DCC-3014 (vimseltinib) is a CSF1R inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with tenosynovial giant cell tumor.

                            Brand Name : DCC-3014

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 15, 2024

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EMA Accepts Deciphera’s MAA for Vimseltinib for Tenosynovial Giant Cell Tumor

                            Details : DCC-3014 (vimseltinib) is a CSF1R inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with tenosynovial giant cell tumor.

                            Brand Name : DCC-3014

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 18, 2024

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib...

                            Details : DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.

                            Brand Name : DCC-3014

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 30, 2023

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib i...

                            Details : DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.

                            Brand Name : DCC-3014

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 01, 2023

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $143.7 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwrite...

                            Details : Deciphera intends to use the proceeds to fund its planned Phase 3 INSIGHT study of QINLOCK versus sunitinib, to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tum...

                            Brand Name : DCC-3014

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 24, 2023

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $143.7 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

                            Details : Deciphera intends to use the net proceeds from the offering to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway.

                            Brand Name : DCC-3014

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 19, 2023

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock

                            Details : Deciphera intends to use the net proceeds from the offering to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway.

                            Brand Name : DCC-3014

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 18, 2023

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Societ...

                            Details : Updated Results for DCC-3014 (vimseltinib) Showed Objective Response Rate of 69% in Phase 1, 53% in Phase 2 Cohort A, and 46% in Phase 2 Cohort B; Demonstrated a Clinical Benefit Rate of 100% Across All Phase 1/2 Patients.

                            Brand Name : DCC-3014

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 11, 2022

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-31...

                            Details : DCC-3014 (vimseltinib) is an investigational, orally administered, potent and highly selective switch-control kinase inhibitor of CSF1R. Vimseltinib was discovered using our proprietary drug discovery platform and was designed to selectively bind to the ...

                            Brand Name : DCC-3014

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 01, 2022

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Deciphera Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $172.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Ful...

                            Details : Deciphera intends to use the net proceeds from the offering to continue to fund the development of vimseltinib including in its pivotal Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway, additional clinical ...

                            Brand Name : DCC-3014

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 29, 2022

                            Lead Product(s) : Vimseltinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $172.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth